Intellia Therapeutics, Inc. (NTLA) Stock Price & Analysis
Intellia Therapeutics, Inc. (NTLA) closed at USD 11.16 on Thursday, October 22, 2026, down 4.21% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 11.65; the Oct 22, 2026 session ranged USD 10.98–11.97 on volume of 3,650,098 shares. Market capitalization is $1.56B, with a 52-week range of USD 7.95–26.35 (NGM). Source: Nexqual, retrieved October 23, 2026 at 12:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NTLA.md
Key facts (NTLA)
- Last four reported quarters (through Jun 30, 2026): revenue $59.5M, net income -$400M (-672.2% margin), free cash flow -$349M (SEC filings).
- Insider open-market sales, last ~7 months: 5 Form 4 filings, $530K; 3 not under a Rule 10b5-1 plan ($159K); 0 by opportunistic insiders, 1 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 2.75 on a 1–5 scale) (20 analysts), mean target USD 23.11 (range 8–61).
- Total return with dividends: 1Y -56.9% vs S&P 500 +14.9%; 5Y -91.5% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.79, revenue estimate $9.8M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (NTLA)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $33.1M | $52.1M | $36.3M | $57.9M | $67.7M | $59.5M |
| Gross profit | $33.1M | — | — | — | — | — |
| Operating income | -$268M | -$458M | -$515M | -$534M | -$441M | -$423M |
| Net income | -$268M | -$474M | -$481M | -$519M | -$413M | -$400M |
| EPS (diluted) | -$3.78 | -$6.16 | -$5.42 | -$5.25 | -$3.81 | — |
| Free cash flow | -$238M | -$347M | -$408M | -$355M | -$396M | -$349M |
| Gross margin | 100.0% | — | — | — | — | — |
| Operating margin | -810.4% | -879.0% | -1420.5% | -923.1% | -651.7% | -711.7% |
| Net margin | -810.5% | -909.8% | -1326.5% | -896.8% | -609.9% | -672.2% |
| Revenue growth | -43.0% | +57.7% | -30.4% | +59.6% | +16.9% | — |
| Cash + short-term investments | $749M | $1.19B | $912M | $602M | $450M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (NTLA)
P/S 26.3x · P/B 2.1x · FCF yield -22.30% · Earnings yield -25.58%
Insider sales (SEC Form 4, open-market, last ~7 months) (NTLA)
2 of 5 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | Dube Michael P | VP, Chief Accounting Officer | 1,864 | $23K | 2.8% | No | Too little history (no open-market trades in 2023) |
| 2026-08-20…2026-08-21 | Leonard John M | President and CEO | 22,675 | $287K | 1.8% | Yes (adopted May 21, 2026) | Routine (sold in Jan each year 2023–2025; this trade is outside those months) |
| 2026-07-22 | Dulac Edward J Iii | EVP, Chief Financial Officer | 8,111 | $91K | 5.2% | No | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-02 | Dulac Edward J Iii | EVP, Chief Financial Officer | 4,677 | $84K | 2.9% | Yes (adopted September 8, 2025) | Too little history (no open-market trades in 2023 or 2024) |
| 2026-07-01 | Dube Michael P | VP, Chief Accounting Officer | 2,641 | $44K | 3.8% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (NTLA)
Consensus Hold (mean 2.75 on a 1–5 scale), 20 analysts; mean target USD 23.11 (low 8, high 61).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | Barclays | Initiated | Underweight | $8 |
| 2026-09-09 | Citizens | Reiterated | Market Outperform | $30 |
| 2026-09-09 | Wedbush | Target raised | Neutral | $12 → $13 |
| 2026-09-09 | HC Wainwright & Co. | Reiterated | Buy | $25 |
| 2026-08-25 | Citizens | Reiterated | Market Outperform | $30 |
| 2026-08-07 | Evercore ISI Group | Upgrade | In-Line → Outperform | $16 → $24 |
| 2026-07-16 | Wolfe Research | Downgrade | Peer Perform → Underperform | $9 |
| 2026-07-10 | Wedbush | Target raised | Neutral | $12 → $17 |
Total return (dividends reinvested) (NTLA)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -56.9% | -91.5% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -57.0% | -38.9% |
| Volatility (annualized) | 96.6% | 79.1% |
| Max drawdown | -69.0% (Oct 2025→Nov 2025) | -95.1% (Nov 2021→Mar 2025) |
NTLA suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | REGENERON PHARMACEUTICALS, INC. (REGN) | “Our technological advancements and any potential for revenue may be derived in part from our collaborations, including, for example, with Regeneron Pharmaceuticals, Inc. ("Regeneron"), and if the collaboration or co-development agreements related to a material collaboration were to be terminated or materially altered in an adverse manner, our business, financial condition, results of operations and prospects would…” |
| Partner | Caribou Biosciences, Inc. (CRBU) | “We co-own some of these patent portfolios with our collaboration partners, such as Regeneron, and we have in-licensed some of these patent portfolios from licensors, including Caribou Biosciences, Inc. ("Caribou") and others.” |
| Partner | AvenCell Therapeutics | “AvenCell Therapeutics, Inc. ("AvenCell") was formed in July 2021 as a joint venture between us, Cellex Cell Professionals GmbH ("Cellex") and funds managed by Blackstone Life Sciences Advisors L.L.C. ("BXLS").” |
| Partner | Kyverna Therapeutics, Inc. (KYTX) | “In December 2021, we entered into a licensing and collaboration agreement with Kyverna Therapeutics, Inc. ("Kyverna"), a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases, for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases.” |
| Partner | Cellex Cell Professionals | “AvenCell Therapeutics, Inc. ("AvenCell") was formed in July 2021 as a joint venture between us, Cellex Cell Professionals GmbH ("Cellex") and funds managed by Blackstone Life Sciences Advisors L.L.C. ("BXLS").” |
| Partner | Blackstone Life Sciences Advisors | “AvenCell Therapeutics, Inc. ("AvenCell") was formed in July 2021 as a joint venture between us, Cellex Cell Professionals GmbH ("Cellex") and funds managed by Blackstone Life Sciences Advisors L.L.C. ("BXLS").” |
| Partner | CRISPR Therapeutics AG (CRSP) | “For example, with respect to our sublicensed rights from Caribou to UC/Vienna/Charpentier intellectual property, UC retained the right to control the prosecution, enforcement and defense of this intellectual property in its license agreement with Caribou and, pursuant to an Invention Management Agreement, shares these responsibilities with CRISPR Therapeutics AG and, under certain circumstances, ERS Genomics, Ltd.…” |
| Partner | ERS Genomics | “For example, with respect to our sublicensed rights from Caribou to UC/Vienna/Charpentier intellectual property, UC retained the right to control the prosecution, enforcement and defense of this intellectual property in its license agreement with Caribou and, pursuant to an Invention Management Agreement, shares these responsibilities with CRISPR Therapeutics AG and, under certain circumstances, ERS Genomics, Ltd.…” |
Quoted from the company's 10-K filed Feb 26, 2026.
Companies that name NTLA in their SEC reports
| Relationship to NTLA | Company | Filing | Sentence |
|---|---|---|---|
| partner | Kyverna Therapeutics, Inc. (KYTX) | 10-K Mar 26, 2026 | “To that end, we established a partnership with Intellia to create allogeneic T-cell therapies.” |
| partner | Caribou Biosciences, Inc. (CRBU) | 10-K Mar 5, 2026 | “On July 16, 2014, we entered into a License Agreement (as amended, "Intellia Agreement") with Intellia, LLC (now Intellia Therapeutics, Inc.), under which we granted Intellia an exclusive worldwide license, with the right to sublicense, to certain CRISPR-Cas9 technology for a defined field of human therapeutics in exchange for Intellia stock.” |
| partner | REGENERON PHARMACEUTICALS, INC. (REGN) | 10-K Feb 4, 2026 | “See the "Collaboration, License, and Other Agreements" section below for descriptions of our agreements with Alnylam Pharmaceuticals, Inc. and Intellia Therapeutics, Inc.” |
NTLA company outlook (results filed Aug 6, 2026)
- “The company's existing cash resources are expected to fund its operations at least into 2028 and well beyond lonvo-z's anticipated U.S. commercial launch for HAE in the first half of 2027.”
- “This guidance excludes all potential commercial revenues from lonvo-z. • Collaboration Revenue : Collaboration revenue was $7.7 million for the second quarter of 2026, compared to $14.2 million for the second quarter of 2025.”
- “("Regeneron") and their co-development program for ATTR amyloidosis; and its growth as a company and expectations regarding its uses of capital, expenses, future accumulated deficit and financial results, including its ability to fund operations at least into 2028 and well beyond lonvo-z's anticipated U.S. commercial launch for HAE in the first half of 2027.”
Quoted word-for-word from the SEC 8-K results press release.
NTLA analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.79 | $-0.78 | +0.7% | $9.8M | 16 |
| Next quarter (ends Dec 2026) | $-0.75 | $-0.77 | -1.9% | $17.1M | 16 |
| Current fiscal year (ends Dec 2026) | $-3.14 | $-3.14 | +0.1% | $51.9M | 17 |
| Next fiscal year (ends Dec 2027) | $-2.56 | $-1.76 | +45.9% | $126.3M | 17 |
NTLA options: expected move
Options price a move of about ±18.3% (±$2.05) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 82.1% | ±18.3% |
| Dec 18, 2026 | 56 | 76.6% | ±23.9% |
| Jan 15, 2027 | 84 | 74.9% | ±28.6% |
| Apr 16, 2027 | 175 | 78.9% | ±38.2% |
30-day implied volatility 72.1% vs 55.3% realized over the last 30 trading days. Put/call ratio (volume) 0.27. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 12:51 UTC)
| Price | USD 11.16 |
|---|---|
| Change | ▼ 4.21% (down) |
| Previous Close | USD 11.65 |
| Open | USD 11.41 |
| Day Range | USD 10.98 – 11.97 |
| 52-Week Range | USD 7.95 – 26.35 |
| Volume | 3,650,098 shares |
| Market Cap | $1.56B |
| Exchange | NGM |
Technical Analysis (NTLA)
Nexqual's technical model rates NTLA "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 12:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 39.86 (neutral) |
| vs SMA50 | Below (USD 12.22) |
| MACD | -0.2 (negative) |
Analyst Ratings (NTLA)
Wall Street analysts rate NTLA "Hold" based on 20 analysts, with a mean price target of USD 23.11 (range USD 8–61), per Nexqual as of October 23, 2026 at 12:51 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 23.11 |
| High Target | USD 61 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 10 / 6 / 4 |
Earnings (NTLA)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.79 |
| Revenue Estimate | $9.77M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.8 vs est -0.78 ▼ miss |
| 2026-03-31 | USD -0.81 vs est -0.9 ▲ beat |
| 2025-12-31 | USD -0.83 vs est -0.96 ▲ beat |
| 2025-09-30 | USD -0.92 vs est -0.98 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financials & Fundamentals (NTLA)
| Total Revenue | $59.51M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -46.20% |
| Gross Margin | +0.00% |
| Operating Margin | -1472.26% |
| Profit Margin | +0.00% |
| ROE | -55.44% |
| Debt / Equity | 0.1 |
| Current Ratio | 6.65 |
| Total Cash | $437.76M |
| Total Debt | $73.41M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$348.69M (-586.0% of revenue) |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financial Health Score (NTLA)
Nexqual rates Intellia Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 12:51 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $438M cash vs $73M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$349M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -55%, ROA -30.1% |
Ownership (NTLA)
| Insider Ownership | +3.84% |
|---|---|
| Institutional Ownership | +100.11% |
| Shares Outstanding | 140.13M |
| Float | 134.21M |
| Short % of Float | +40.55% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Leadership (NTLA)
Intellia Therapeutics, Inc. is led by John M. Leonard, President, CEO & Director, per Nexqual as of October 23, 2026 at 12:51 UTC.
| President, CEO & Director | John M. Leonard |
|---|---|
| Executive VP, CFO & Treasurer | Edward J. Dulac |
| Executive VP & Chief Scientific Officer | Birgit Schultes |
Major Backers & Investors (NTLA)
Notable institutional backers of Intellia Therapeutics, Inc. include ARK Invest, Shaw D.E. & Co., Inc., Two Sigma Investments, LP, according to Nexqual as of October 23, 2026 at 12:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| ARK Invest | 12.04% |
| Shaw D.E. & Co., Inc. | 4.6% |
| Two Sigma Investments, LP | 3.74% |
| FMR, LLC | 3.41% |
| RA Capital Management, L.P. | 3.23% |
| Regeneron Pharmaceuticals Inc | 2.64% |
| Fidelity | 2.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11% |
| Vanguard Group | 9.53% |
| State Street | 6.59% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
From Intellia Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- The potential application of our proprietary technologies, including CRISPR gene editing, is extremely broad, and we plan to continue to identify partners who can contribute meaningful resources and insights to our programs and allow us to more rapidly bring scientific innovation to a broader patient population.
- We aim to remain a pioneer in the field by developing additional product candidates that leverage our proprietary technologies acquired or developed over a decade-plus of research and development, including multi-modal CRISPR gene editing, LNP, and oligonucleotide technologies.
- The following table summarizes the status of our research and development programs: We are the first company to advance in vivo genome editing product candidates into Phase 3 development.
- To accelerate the development and commercialization of therapeutic products that use our proprietary technologies in multiple therapeutic areas, we have formed, and intend to seek other opportunities to form, strategic alliances with collaborators who can augment our leadership in the development of therapeutic products.
Partnerships
- Our strategy is to (1) advance the clinical development of our lead CRISPR-based product candidates, (2) build and leverage a fully integrated commercial-stage infrastructure, (3) expand our pipeline utilizing our expertise and proprietary technologies, and (4) collaborate with partners to expand our technology reach and maximize our return on investment.
- In April 2016, we entered into a license and collaboration agreement with Regeneron (as amended from time to time, the "2016 Regeneron Agreement").
Legal & Regulatory Risks (Item 1A, quoted)
- Risks Related to Obtaining Regulatory Approval
- We are currently conducting and may in the future conduct other clinical trials for our product candidates outside the U.S., and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
- We are currently conducting our Phase 3 clinical trials of nex-z (pending resolution of the clinical hold on the IND for the MAGNITUDE clinical trial) and for lonvo-z, and may in the future conduct clinical trials for our other product candidates, outside the U.S.
- We have received orphan drug designation for nex-z and lonvo-z and may in the future seek orphan drug designation for some of our other product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our revenue, if any, to be reduced.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt